<< Back To Search

Personalized NK Cell Therapy in CBT

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
This is a study to see if personalized natural killer (NK) cell therapy works well for patients with certain types of cancer after chemotherapy and cord blood transplant. They will be checking if choosing cord blood based on specific markers and using NK cells can kill cancer cells and reduce certain risks.
*Third Opinion AI Generated Synopsis

Trial Summary
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1/x recipients based on HLA-killer-cell immunoglobulin-like receptor (KIR) typing, and adoptive therapy with CB-derived NK cells for HLA-C2/C2 patients. Natural killer cells may kill tumor cells that remain in the body after chemotherapy treatment and lessen the risk of graft versus host disease after cord blood transplant.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?